An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1a: Dose-limiting toxicities (DLTs)

  Measured over: Up to 28 days

• Part 1a and Part 1b: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)

  Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 14 months

• Part 1a and Part 1b: Number of Participants with dose adjustments

  Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 14 months

• Part 1a and Part 1b: Dose Intensity

  Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 14 months

• Part 1a and Part 1b: Duration of exposure to each study drug

  Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 14 months

• Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at Month 6

  Measured over: Month 6

Changes Tremor has spotted